<- Go Home
Urologix, Inc.
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States.
Market Cap
$21.00
Volume
35.5K
Cash and Equivalents
$492.0K
EBITDA
-$373.0K
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$5.7M
Profit Margin
47.13%
52 Week High
$0.00
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
-0.00
Price / Earnings
-0.00
Price / Tangible Book Value
-0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$874.0K
Return on Equity
80.78%
Return on Assets
-7.62
Cash and Short Term Investments
$492.0K
Debt
$5.3M
Equity
-$8.1M
Revenue
$12.0M
Unlevered FCF
$1.2M
Sector
Health Care Equipment and Supplies
Category
N/A